{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T09:03:01Z","timestamp":1648890181302},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s00393-012-0984-x","type":"journal-article","created":{"date-parts":[[2012,11,8]],"date-time":"2012-11-08T12:39:21Z","timestamp":1352378361000},"page":"760-764","source":"Crossref","is-referenced-by-count":0,"title":["Update Morbus Beh\u00e7et"],"prefix":"10.1007","volume":"71","author":[{"given":"I.","family":"K\u00f6tter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,10]]},"reference":[{"key":"984_CR1","first-page":"1078","volume":"335","author":"International","year":"1990","unstructured":"International Study Group for Behcet\u2019s Disease (1990) Criteria for diagnosis of Behcet\u2019s disease. Lancet 335:1078\u20131080","journal-title":"Lancet"},{"key":"984_CR2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E et al (2011) Anti-TNF agents for Behcet\u2019s disease: analysis of published data on 369 Patients. Semin Arthritis Rheum 41(1):61\u201370","journal-title":"Semin Arthritis Rheum"},{"key":"984_CR3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10067-009-1279-8","volume":"29","author":"Bilginer","year":"2010","unstructured":"Bilginer Y, Ayaz NA, Ozen S (2010) Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behcet\u2019s disease. Clin Rheumatol 29:209\u2013210","journal-title":"Clin Rheumatol"},{"key":"984_CR4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7326\/0003-4819-149-4-200808190-00018","volume":"149","author":"Botsios","year":"2008","unstructured":"Botsios C, Sfriso P, Furlan A et al (2008) Resistant Behcet disease responsive to anakinra. Ann Intern Med 149:284\u2013286","journal-title":"Ann Intern Med"},{"key":"984_CR5","unstructured":"Cantarini L, Vitale A, Borri M et al (2012) Successful use of canakinumab in a patient with resistant Behcet\u2019s disease. Clin Exp Rheumatol [Epub ahead of print]"},{"key":"984_CR6","first-page":"880","volume":"16","author":"Chi","year":"2010","unstructured":"Chi W, Yang P, Zhu X et al (2010) Production of interleukin-17 in Behcet\u2019s disease is inhibited by cyclosporin A. Mol Vis 16:880\u2013886","journal-title":"Mol Vis"},{"key":"984_CR7","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s10067-011-1694-5","volume":"30","author":"Davatchi","year":"2011","unstructured":"Davatchi F, Chams-Davatchi C, Ghodsi Z et al (2011) Diagnostic value of pathergy test in Behcet\u2019s disease according to the change of incidence over the time. Clin Rheumatol 30:1151\u20131155","journal-title":"Clin Rheumatol"},{"key":"984_CR8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10067-010-1574-4","volume":"30","author":"Davatchi","year":"2011","unstructured":"Davatchi F, Shahram F, Shams H et al (2011) Gender influence on ocular manifestations and their outcome in Behcet\u2019s disease. A long-term follow-up of up to 20 years. Clin Rheumatol 30:541\u2013547","journal-title":"Clin Rheumatol"},{"key":"984_CR9","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","volume":"13","author":"Davatchi","year":"2010","unstructured":"Davatchi F, Shams H, Rezaipoor M et al (2010) Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single-blind control study (pilot study). Int J Rheum Dis 13:246\u2013252","journal-title":"Int J Rheum Dis"},{"key":"984_CR10","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","volume":"62","author":"Deuter","year":"2010","unstructured":"Deuter CM, Zierhut M, Mohle A et al (2010) Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet\u2019s disease. Arthritis Rheum 62:2796\u20132805","journal-title":"Arthritis Rheum"},{"key":"984_CR11","unstructured":"Dilsen N, Konice M, Aral O (1985) Our diagnostic criteria of Behcet\u2019s disease\u2014an overview. In: Lehner T, Barnes CG (Hrsg) Recent advances in Behcet\u2019s disease. Royal Society of Medicine Services, London, S\u00a0177\u2013180"},{"key":"984_CR12","first-page":"86","volume":"28","author":"Direskeneli","year":"2010","unstructured":"Direskeneli H, Mumcu G (2010) A possible decline in the incidence and severity of Behcet\u2019s disease: implications for an infectious etiology and oral health. Clin Exp Rheumatol 28:86\u201390","journal-title":"Clin Exp Rheumatol"},{"key":"984_CR13","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/jid.2010.114","volume":"130","author":"Ekinci","year":"2010","unstructured":"Ekinci NS, Alpsoy E, Karakas AA et al (2010) IL-17A has an important role in the acute attacks of Behcet\u2019s disease. J Invest Dermatol 130:2136\u20132138","journal-title":"J Invest Dermatol"},{"key":"984_CR14","first-page":"3","volume":"29","author":"Gul","year":"2011","unstructured":"Gul A (2011) Genome-wide association studies in Behcet\u2019s disease: expectations and promises. Clin Exp Rheumatol 29:3\u20135","journal-title":"Clin Exp Rheumatol"},{"key":"984_CR15","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/annrheumdis-2011-155143","volume":"71","author":"Gul","year":"2012","unstructured":"Gul A, Tugal-Tutkun I, Dinarello CA et al (2012) Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet\u2019s disease: an open-label pilot study. Ann Rheum Dis 71:563\u2013566","journal-title":"Ann Rheum Dis"},{"key":"984_CR16","doi-asserted-by":"crossref","unstructured":"Hamuryudan V, Hatemi G, Tascilar K et al (2010) Prognosis of Behcet\u2019s syndrome among men with mucocutaneous involvement at disease onset: long-term outcome of patients enrolled in a controlled trial. Rheumatology (Oxford) 49:173\u2013177","DOI":"10.1093\/rheumatology\/kep350"},{"key":"984_CR17","first-page":"71","volume":"29","author":"Hamzaoui","year":"2011","unstructured":"Hamzaoui K (2011) Th17 cells in Behcet\u2019s disease: a new immunoregulatory axis. Clin Exp Rheumatol 29:71\u201376","journal-title":"Clin Exp Rheumatol"},{"key":"984_CR18","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5021\/ad.2011.23.3.313","volume":"23","author":"Han","year":"2011","unstructured":"Han EC, Cho SB, Ahn KJ et al (2011) Expression of pro-inflammatory protein S100A12 (EN-RAGE) in Behcet\u2019s disease and its association with disease activity: a pilot study. Ann Dermatol 23:313\u2013320","journal-title":"Ann Dermatol"},{"key":"984_CR19","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/art.23450","volume":"58","author":"Hatemi","year":"2008","unstructured":"Hatemi G, Fresko I, Tascilar K et al (2008) Increased enthesopathy among Behcet\u2019s syndrome patients with acne and arthritis: an ultrasonography study. Arthritis Rheum 58:1539\u20131545","journal-title":"Arthritis Rheum"},{"key":"984_CR20","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"Hatemi","year":"2008","unstructured":"Hatemi G, Silman A, Bang D et al (2008) EULAR recommendations for the management of Behcet disease. Ann Rheum Dis 67:1656\u20131662","journal-title":"Ann Rheum Dis"},{"key":"984_CR21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s10165-011-0497-5","volume":"22","author":"Hirano","year":"2012","unstructured":"Hirano T, Ohguro N, Hohki S et al (2012) A case of Behcet\u2019s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 22:298\u2013302","journal-title":"Mod Rheumatol"},{"key":"984_CR22","doi-asserted-by":"crossref","unstructured":"Horie Y, Meguro A, Kitaichi N et al (2012) Replication of a microsatellite genome-wide association study of Behcet\u2019s disease in a Korean population. Rheumatology (Oxford) 51:983\u2013986","DOI":"10.1093\/rheumatology\/ker444"},{"key":"984_CR23","first-page":"16","volume":"28","author":"Kim","year":"2010","unstructured":"Kim J, Park JA, Lee EY et al (2010) Imbalance of Th17 to Th1 cells in Behcet\u2019s disease. Clin Exp Rheumatol 28:16\u201319","journal-title":"Clin Exp Rheumatol"},{"key":"984_CR24","doi-asserted-by":"crossref","unstructured":"Kobayashi T, Kishimoto M, Swearingen CJ et al (2012) Differences in clinical manifestations, treatment, and concordance rates with two major sets of criteria for Behcet\u2019s syndrome for patients in the US and Japan: data from a large, three-center cohort study. Mod Rheumatol [Epub ahead of print]","DOI":"10.1007\/s10165-012-0696-8"},{"key":"984_CR25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/annrheumdis-2012-eular.1868","volume":"71","author":"K\u00f6tter","year":"2012","unstructured":"K\u00f6tter I, Nast-Kolb B, Riewerts F et al (2012) Behcet\u2019s disease in Germany: differences and similarities in patients of German and Turkish origin \u2013 a single center experience. Ann Rheum Dis 71:117","journal-title":"Ann Rheum Dis"},{"key":"984_CR26","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/eye.2008.177","volume":"23","author":"Krause","year":"2009","unstructured":"Krause L, Kohler AK, Altenburg A et al (2009) Ocular involvement is associated with HLA-B51 in Adamantiades-Behcet\u2019s disease. Eye 23:1182\u20131186","journal-title":"Eye"},{"key":"984_CR27","first-page":"93","volume":"29","author":"Leccese","year":"2011","unstructured":"Leccese P, Latanza L, D\u2019angelo S et al (2011) Efficacy of switching to adalimumab in a patient with refractory uveitis of Behcet\u2019s disease to infliximab. Clin Exp Rheumatol 29:93","journal-title":"Clin Exp Rheumatol"},{"key":"984_CR28","doi-asserted-by":"crossref","first-page":"5953","DOI":"10.1007\/s11033-011-1407-9","volume":"39","author":"Lee","year":"2011","unstructured":"Lee YH, Choi SJ, Ji JD et al (2011) Genome-wide pathway analysis of a genome-wide association study on psoriasis and Behcet\u2019s disease. Mol Biol Rep 39:5953\u20135959","journal-title":"Mol Biol Rep"},{"key":"984_CR29","doi-asserted-by":"crossref","unstructured":"Liu X, Yang P, Wang C et al (2011) IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet\u2019s disease. Rheumatology (Oxford) 50:293\u2013298","DOI":"10.1093\/rheumatology\/keq330"},{"key":"984_CR30","doi-asserted-by":"crossref","unstructured":"Maldini C, Lavalley MP, Cheminant M et al (2012) Relationships of HLA-B51 or B5 genotype with Behcet\u2019s disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford) 51:887\u2013900","DOI":"10.1093\/rheumatology\/ker428"},{"key":"984_CR31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard.28.2.95","volume":"28","author":"Mason","year":"1969","unstructured":"Mason RM, Barnes CG (1969) Behcet\u2019s syndrome with arthritis. Ann Rheum Dis 28:95\u2013103","journal-title":"Ann Rheum Dis"},{"key":"984_CR32","doi-asserted-by":"crossref","first-page":"38R","DOI":"10.1203\/PDR.0b013e31819dbd0a","volume":"65","author":"Mcgonagle","year":"2009","unstructured":"Mcgonagle D, Aziz A, Dickie LJ et al (2009) An integrated classification of pediatric inflammatory diseases, based on the concepts of autoinflammation and the immunological disease continuum. Pediatr Res 65:38R\u201345R","journal-title":"Pediatr Res"},{"key":"984_CR33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/ng.624","volume":"42","author":"Mizuki","year":"2010","unstructured":"Mizuki N, Meguro A, Ota M et al (2010) Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet\u2019s disease susceptibility loci. Nat Genet 42:703\u2013706","journal-title":"Nat Genet"},{"key":"984_CR34","first-page":"66","volume":"28","author":"Mizushima","year":"1988","unstructured":"Mizushima Y (1988) Revised diagnostic criteria for Behcet\u2019s disease in 1987. Ryumachi 28:66\u201370","journal-title":"Ryumachi"},{"key":"984_CR35","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00296-005-0029-8","volume":"26","author":"Musabak","year":"2006","unstructured":"Musabak U, Pay S, Erdem H et al (2006) Serum interleukin-18 levels in patients with Behcet\u2019s disease. Is its expression associated with disease activity or clinical presentations? Rheumatol Int 26:545\u2013550","journal-title":"Rheumatol Int"},{"key":"984_CR36","first-page":"2371","volume":"36","author":"O","year":"1974","unstructured":"O\u2019Duffy JD (1974) Crit\u00e8res propos\u00e9s pour le diagnostic de la maladie de Behcet. Rev Med 36:2371\u20132379","journal-title":"Rev Med"},{"key":"984_CR37","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s10384-012-0158-z","volume":"56","author":"Ohguro","year":"2012","unstructured":"Ohguro N, Sonoda KH, Takeuchi M et al (2012) The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol 56(5):432\u2013435","journal-title":"Jpn J Ophthalmol"},{"key":"984_CR38","first-page":"54","volume":"29","author":"Olivieri","year":"2011","unstructured":"Olivieri I, Leccese P, D\u2019angelo S et al (2011) Efficacy of adalimumab in patients with Behcet\u2019s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol 29:54\u201357","journal-title":"Clin Exp Rheumatol"},{"key":"984_CR39","doi-asserted-by":"crossref","unstructured":"Perra D, Alba MA, Callejas JL et al (2012) Adalimumab for the treatment of Behcet\u2019s disease: experience in 19 patients. Rheumatology (Oxford) 51(10):1825\u20131831","DOI":"10.1093\/rheumatology\/kes130"},{"key":"984_CR40","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/annrheumdis-2012-eular.1540","volume":"71","author":"Rasmussen","year":"2012","unstructured":"Rasmussen N (2012) The 2012 revised international Chapel Hill consensus nomenclature of the vasculitides. Ann Rheum Dis 71:16","journal-title":"Ann Rheum Dis"},{"key":"984_CR41","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ng.625","volume":"42","author":"Remmers","year":"2010","unstructured":"Remmers EF, Cosan F, Kirino Y et al (2010) Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet\u2019s disease. Nat Genet 42:698\u2013702","journal-title":"Nat Genet"},{"key":"984_CR42","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1002\/art.27568","volume":"62","author":"Saadoun","year":"2010","unstructured":"Saadoun D, Wechsler B, Desseaux K et al (2010) Mortality in Behcet\u2019s disease. Arthritis Rheum 62:2806\u20132812","journal-title":"Arthritis Rheum"},{"key":"984_CR43","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clineuro.2011.10.024","volume":"114","author":"Shapiro","year":"2012","unstructured":"Shapiro LS, Farrell J, Haghighi AB (2012) Tocilizumab treatment for neuro-Behcet\u2019s disease, the first report. Clin Neurol Neurosurg 114:297\u2013298","journal-title":"Clin Neurol Neurosurg"},{"key":"984_CR44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2249.2011.04543.x","volume":"168","author":"Shimizu","year":"2012","unstructured":"Shimizu J, Takai K, Fujiwara N et al (2012) Excessive CD4+ T cells co-expressing interleukin-17 and interferon-gamma in patients with Behcet\u2019s disease. Clin Exp Immunol 168:68\u201374","journal-title":"Clin Exp Immunol"},{"key":"984_CR45","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10165-011-0542-4","volume":"22","author":"Song","year":"2012","unstructured":"Song YW, Kang EH (2012) Behcet\u2019s disease and genes within the major histocompatibility complex region. Mod Rheumatol 22:178\u2013185","journal-title":"Mod Rheumatol"},{"key":"984_CR46","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1186\/ar3824","volume":"14","author":"Sugita","year":"2012","unstructured":"Sugita S, Kawazoe Y, Imai A et al (2012) Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behcet\u2019s disease. Arthritis Res Ther 14:R99","journal-title":"Arthritis Res Ther"},{"key":"984_CR47","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.arcmed.2010.02.002","volume":"41","author":"Touma","year":"2010","unstructured":"Touma Z, Farra C, Hamdan A et al (2010) TNF polymorphisms in patients with Behcet disease: a meta-analysis. Arch Med Res 41:142\u2013146","journal-title":"Arch Med Res"},{"key":"984_CR48","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1136\/annrheumdis-2012-201383","volume":"71","author":"Ugurlu","year":"2012","unstructured":"Ugurlu S, Ucar D, Seyahi E et al (2012) Canakinumab in a patient with juvenile Behcet\u2019s syndrome with refractory eye disease. Ann Rheum Dis 71(9):1589\u20131591","journal-title":"Ann Rheum Dis"},{"key":"984_CR49","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/bjo.2009.168856","volume":"95","author":"Yamada","year":"2011","unstructured":"Yamada Y, Sugita S, Tanaka H et al (2011) Timing of recurrent uveitis in patients with Behcet\u2019s disease receiving infliximab treatment. Br J Ophthalmol 95:205\u2013208","journal-title":"Br J Ophthalmol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-012-0984-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-012-0984-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-012-0984-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:36:10Z","timestamp":1559061370000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-012-0984-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1007\/s00393-012-0984-x","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}